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Abstract: The antineutrophil cytoplasm antibody (ANCA)-associated vasculitides are a 
  spectrum of heterogeneous autoimmune diseases characterized by necrotizing small ves-
sel vasculitis and the presence of ANCA. These chronic multisystem disorders may be 
life-threatening if there is major organ involvement, such as acute renal failure or pulmonary 
hemorrhage, and require significant initial immunosuppression and long-term maintenance 
treatment. Long-established protocols using cyclophosphamide and prednisolone have 
resulted in dramatically improved outcomes for patients since the 1970s. Subsequently, 
international collaboration has contributed to a growing evidence base and consensus in 
the management of these rare disorders. Modifications to traditional treatment protocols by 
the use of azathioprine or methotrexate rather than cyclophosphamide, and the introduction 
of newer agents, such as rituximab, has maintained outcomes whilst decreasing toxicity. 
However, the treatment limitations of incomplete efficacy, infection, and cumulative toxicity 
persist. These issues have continued to drive the search for safer and more effective modu-
lation of the immune system using targeted immunotherapy. This review will explore the 
current evidence base for management of ANCA-associated vasculitis and future treatment 
prospects.
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Introduction
The antineutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAV) are 
characterized by the production of ANCA, reactive to either proteinase-3 (PR3-ANCA) 
or myeloperoxidase (MPO-ANCA), which are constituents of neutrophil granules 
and monocyte lysosomes. AAV are idiopathic multisystem vasculitides which cause 
destructive inflammation of mainly small caliber arterial vessels and comprise several 
clinically and pathologically defined disease entities: Wegener’s granulomatosis (WG), 
microscopic polyangiitis (MPA), renal-limited vasculitis (RLV) and Churg–Strauss 
syndrome (CSS).
AAV cause considerable morbidity and mortality, with end-stage renal failure 
developing in over 20% of patients at five years.1 Prior to the introduction of steroids 
and cyclophosphamide (CYP) in the early 1970s, survival was uniformly dismal, with 
a median survival of five months for patients with generalized WG.2 In contrast, induc-
tion of remission is now achieved in over 90% patients by six months,3 and five-year 
survival rates are around 75%.4 However, even with best available therapy, relapse 
rates remain unacceptably high at up to 50% over five years,5 as does treatment-related 
morbidity and mortality.Therapeutics and Clinical Risk Management 2010:6 254
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Long-term management of these conditions therefore 
requires balancing the burden of immunosuppression with 
control of disease activity, and the impetus remains to refine 
these protocols and to investigate newer agents that might 
be equipotent but less toxic. A robust evidence base for 
treatment regimens has historically been limited. However, 
the European Vasculitis Study Group (EUVAS) has fostered 
international collaboration and conducted prospective 
studies addressing optimal therapy that have led to some 
treatment consensus. Factors initiating disease and causing 
relapse remain poorly defined and therefore it is imperative 
to understand the pathogenesis of these conditions better, 
so that more targeted and less toxic therapeutic protocols 
can be devised.
Clinical features
AAV are characterized by a focal necrotizing vasculitis 
affecting arterioles, capillaries, and venules which can 
affect virtually any organ with varying degrees of severity. 
Overall, the lungs (Figure 1) and kidneys (Figure 2) are the 
most commonly involved organs, in around 70%–80% of 
patients.6 There is heterogeneity between and within disease 
entities in relation to extent and prognosis, and the Chapel 
Hill Consensus Conference nomenclature7 is one of the 
most widely used vasculitis classification systems. AAV 
most commonly occur in the elderly and the incidence is 
approximately 20 cases/million/year.8
WG is characterized by granulomatous inflammation of 
the upper and lower respiratory tract and a high rate of relapse. 
Granulomatous lung disease may be difficult to distinguish 
from mycobacterial infection. Ear, nose and throat disease 
in WG may be aggressive, with classical necrosis and col-
lapse of the nasal bridge, epistaxis, conductive deafness 
due to Eustachian tube dysfunction, or subglottic stenosis. 
Orbital disease in WG includes necrotizing scleritis and 
primary orbital disease which may present with proptosis. 
Both of these features and their attendant complications 
may pose a severe risk to vision. WG is usually associated 
with PR3-ANCA. In contrast, patients with MPA have small 
vessel inflammation without granulomata, more often with 
MPO-ANCA. CSS is characterized by late-onset asthma and 
eosinophilia, sometimes with rhinitis or nasal polyps, and 
ANCA more usually reactive to MPO. Renal-limited vasculi-
tis is an isolated pauci-immune crescentic glomerulonephritis 
in which MPO- or PR3-ANCA may be found.
Patients with generalized disease may present with active 
renal vasculitis or another immediate threat to life or organ 
function. Without treatment, the most serious complications of 
pulmonary hemorrhage and rapidly progressive glomerulone-
phritis may be rapidly fatal. Limited disease refers to patients 
with AAV and one or more involved organ systems, but no 
renal disease or immediately life-threatening complications 
(Table 1).9 The intensity (and therefore tolerated potential 
toxicity) of treatment depends on disease severity. Interest-
ingly, only about 60% of patients with limited disease will be 
ANCA-positive and more than 10% of patients with pauci-
immune glomerulonephritis thought to be due to AAV will be 
ANCA-negative.10 Overall, the accumulation of chronic tissue 
damage with fibrosis and scarring contributes significantly to 
morbidity. Patients are closely monitored by review of clinical 
Figure 2 Renal biopsy from a patient with AAV and severe renal failure showing a 
  glomerulus containing an extensive cellular crescent with a break in the basement mem-
brane and surrounding fibrin deposition (arrowed) Methenamine silver stain, X400.
Abbreviation: AAV, ANCA-associated vasculititis.
Figure 1 Chest radiograph showing multiple cavitating lung lesions in a patient with 
Wegener’s granulomatosis.Therapeutics and Clinical Risk Management 2010:6 255
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symptoms and signs, urinalysis, and imaging and laboratory 
blood tests, including autoantibody levels by indirect immu-
nofluorescence for ANCA or antigen-specific ELISA for anti-
PR3 or anti-MPO antibodies. Disease activity and severity 
may be assessed using the well-characterized Birmingham 
Vasculitis Activity Score,11 while disease-induced damage 
is measured by the Vasculitis Damage Index.12 These scores 
have been mostly used as research and clinical trial tools 
enabling comparison of patients, but may be used to facilitate 
patient management.
Pathogenesis
Both cellular and humoral arms of the immune system 
are involved in the disease. The production of ANCA is a 
hallmark of the small vessel vasculitides. However, T-cells, 
  macrophages, and other components of the immune system 
have all been implicated in causation of disease. Better 
understanding of pathogenesis is clearly required to develop 
a treatment rationale for specific immunotherapies. However, 
it is unclear to what extent these heterogeneous conditions 
share similar pathologic mechanisms. ANCA are specific 
for the serine protease PR3 or for MPO, both of which are 
constituents of azurophilic neutrophil granules and monocyte 
lysosomes. In vitro studies indicate that cytokine-primed 
neutrophils and monocytes express PR3 and MPO on their 
cell membranes. ANCA bind to the cell surface by both 
Fc receptor engagement13 and (Fab’)2 binding,14 thereby 
activating the cell. Neutrophils activated by ANCA release 
oxygen radicals, lytic enzymes, and inflammatory cytokines, 
such as IL-8.15,16 This in turn impedes neutrophil migration17 
and results in excessive neutrophil accumulation within 
the vasculature, allowing the released reactants to dam-
age the endothelium and cause vessel inflammation.18 The 
normal process of noninflammatory clearance of apoptotic 
  neutrophils by professional phagocytes is disrupted by 
ANCA15,19 and, as a result, neutrophils are likely to undergo 
proinflammatory secondary necrosis. The presence of ANCA 
has been shown to promote adhesion and transmigration 
of primed neutrophils across tumor necrosis factor (TNF)-
stimulated endothelium.17
The most compelling in vivo evidence for the pathogenic-
ity of ANCA in humans comes from a single case report of 
pulmonary hemorrhage and glomerulonephritis in a neonate 
with transplacental transfer of ANCA IgG from a mother 
with active MPO-ANCA vasculitis.20 Furthermore, recent 
in vivo animal models of MPO-ANCA vasculitis suggest 
that, at least in the rodent, MPO-ANCA are sufficient to 
generate glomerulonephritis and renal vasculitis, in the 
absence of antigen-specific T-cells.21 In addition, the renal 
injury in this model is dependent on complement activation22 
and on the presence of neutrophils.23 In rats injected with 
MPO, MPO-ANCA are associated with focal necrotising 
glomerulonephritis, enhance leucocyte-endothelial interac-
tions, and promote microvascular injury.24 In wild-type mice, 
transfer of murine PR3-ANCA has been shown to amplify 
local inflammation,25 although no convincing model of PR3-
ANCA vasculitis has been reported. In addition, no cases of 
human disease transfer by PR3-ANCA have been reported.
What triggers the formation of ANCA is unknown, but 
a role for septic episodes preceding episodes of AAV has 
been suggested.26 This has received more attention recently 
with a proposed model of molecular mimicry between ANCA 
targets and bacterial fimbrial adhesion proteins.27 Patients 
with focal necrotizing crescentic glomerulonephritis have 
a high prevalence of circulating autoantibodies against 
lysosomal-associated membrane protein-2 (LAMP-2), a 
heavily glycosylated type 1 membrane protein involved in 
cellular adhesion and homeostasis, and the majority of these 
anti-LAMP-2-positive patients are also ANCA-positive. 
Therefore, it is plausible that an early immune response to 
pathogen-derived peptides which show significant homol-
ogy with peptide sequences in ANCA target antigens results 
in immune cross-reactivity. A central role for infections 
as triggers of disease has also been suggested following 
the description of anticomplementary PR3 antibodies in a 
proportion of patients with PR3-ANCA vasculitis.28 These 
antibodies react to peptide sequences from the complemen-
tary PR3-sequence, which has significant homology with a 
number of infectious pathogens, including Staphylococcus 
aureus, previously implicated in disease relapse.29 It has 
been proposed that antibodies induced by infection, which 
are cross-reactive to the complementary PR3 peptide, can 
Table 1 EUVAS disease categorization of ANCA-associated 
vasculitis9
Category Definition
Localized Upper and/or lower respiratory tract 
disease without any other systemic 
  involvement or constitutional symptoms
Early systemic Any, without organ-threatening or life-
threatening disease
Generalized Renal or other organ threatening disease, 
serum creatinine 500 µmol/L (5.6 mg/dL)
Severe Renal or other vital organ failure, serum 
creatinine 500 µmol/L (5.6 mg/dL)
Refractory Progressive disease unresponsive to 
  glucocorticoids and cyclophosphamideTherapeutics and Clinical Risk Management 2010:6 256
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then act as immunologic templates for anti-PR3 antibodies. 
Regardless of the exact molecular mechanism operating, 
infections appear to be a critical stimulus for inducing 
immune responsiveness, and their prevention may promote 
prolonged disease-free remissions.30
Paradoxically, in patients with AAV , the renal lesions are 
pauci-immune, characterized by little or no immunoglobulin 
deposition, but cellular infiltration with T-lymphocytes and 
macrophages,31 and there is now significant evidence for 
the role of cellular mediators, particularly T-cells, in AAV . 
WG is characterized by granulomatous lesions, typical 
of a delayed-type hypersensitivity reaction and reflecting 
a cellular immune response.32 T-cells have been further 
implicated in the process because patients’ lymphocytes 
show in vitro reactivity to PR3 or MPO autoantigens,33 and 
T-cell directed therapy can treat disease.34 Th17 cells are 
implicated in autoimmunity and are likely to play a role in 
the pathogenesis of AAV . Work in our laboratory has shown 
that patients with AAV have elevated levels of IL-17 and 
some patients have ANCA-specific memory Th17-cells.35 
Monocyte activation has also been demonstrated in AAV, 
with elevated levels of IL-6 and neopterin in acute disease 
but not in convalescence.36
In terms of genetic risk determinants, patients with 
WG have higher than expected carriage of the Z allele for 
the protease inhibitor gene, which confers α1-antitrypsin 
deficiency.37 Single nucleotide polymorphisms in the IL-2 
receptor have been associated with systemic lupus ery-
thematosus (SLE) and also with AAV,38 and CTLA4 and 
PTPN22 have been identified as susceptibility loci in AAV .39 
Patients with AAV and PR3-ANCA have higher neutrophil 
membrane expression of PR3 which is genetically deter-
mined and related to relapse.40 Finally, analysis of leucocyte 
gene expression profiles in patients has demonstrated that 
ANCA signature genes are expressed on neutrophils and 
can be differentiated from healthy donors and patients with 
SLE.41 However, no clear link with major histocompatibility 
  antigens has so far been demonstrated.
Current treatment
Treatment of AAV can be divided into two phases, ie, initial 
immunosuppression for rapid and effective onset of remission 
and subsequent maintenance therapy to prevent relapse. The 
ideal regimen would minimize toxicity whilst maintaining 
high levels of treatment success. The introduction of steroids 
and CYP in the 1970s transformed outcomes for patients 
with AAV, and subsequent multicenter randomized trials 
have optimized their use. Consensus regarding indications for 
plasma exchange (PE), the use of azathioprine (AZA) rather 
than CYP in maintenance treatment, and the introduction 
of methotrexate (MTX) for induction in less severe disease 
has come about as a result of trials conducted by EUVAS. 
However, despite significant evidence-based modification of 
standard treatment protocols, 90% of patients will experience 
drug-related toxicity, which is severe in 25%–50% of cases.42 
Age and serum creatinine at diagnosis are the strongest pre-
dictors of both patient and renal survival, and elderly patients 
have significantly higher early mortality.5
Induction therapy
Advanced renal failure at presentation correlates with an 
increased risk of end-stage renal failure and death, and these 
patients are treated aggressively with CYP and high-dose 
intravenous (IV) steroids. However, this is associated with a 
significant risk of treatment-related morbidity and mortality, 
especially in older patients. Infectious adverse effects are the 
most common cause of death or severe morbidity, and their 
frequency is associated with increased age as well as steroid 
dosage and leucopenia secondary to immunosuppressive 
therapy. A diagnosis of WG, rather than MPA, and anti-PR3 
rather than anti-MPO antibodies, are further markers of 
a poor prognosis, with increased risk of disease relapse.5 
Therefore, intensity of treatment during the induction phase 
depends on both the extent and severity of disease, but almost 
invariably consists of glucocorticoids with a second agent. 
Serum creatinine, ANCA titer, and acute phase response all 
usually improve with induction treatment (Figure 3). Current 
EUVAS trials are attempting to define equipotent but less 
toxic induction regimens, based on the use of agents such 
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Figure 3 Biochemical changes over time in a patient with PR3-ANCA demonstrat-
ing rapid decrease in serum creatinine, ANCA titer and C-reactive protein following 
initiation of immunosuppression.
Abbreviations:  ANCA, antineutrophil cytoplasm antibody; PR3-ANCA, proteinase-3 
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as rituximab (RTX) and mycophenolate mofetil (MMF, see 
www.vasculitis.org).
Cyclophosphamide and glucocorticoids
For many years, CYP has formed part of the usual high-dose 
regimen for induction of remission in severe disease. CYP 
is an alkylating agent which is an inactive cyclic phospha-
mide ester of mechlorethamine. It is transformed via hepatic 
and intracellular enzymes to active alkylating metabolites, 
ie, 4-hydroxycyclophophosphamide, aldophosphamide, acro-
lein, and phosphoramide mustard. The alkylated purine bases 
result in the inhibition of DNA and RNA synthesis and func-
tion, and eventually promote cellular apoptosis. Side effects 
of CYP are significant and cumulative, including short-term 
risks of hemorrhagic cystitis, leucopenia, and sepsis, as well 
as long-term risks of bladder cancer, lymphoproliferative 
disease, myelodysplasia, and gonadotoxicity.
The initial regimen was developed at the National 
Institutes of Health (NIH) and originally consisted of 
CYP at 2 mg/kg/day and glucocorticoids at 1 mg/kg/day.43 
CYP was continued for at least one year after remission 
and steroids were tapered to an alternate day regimen, but 
also continued for one year. This regimen reliably induces 
remission in over 80% of patients, but causes significant 
toxicity and morbidity,6 and relapses occur in up to 50% 
of patients, despite continued immunosuppression.5,6,43 
Numerous refinements of this approach have been tested in 
clinical trials. A number of randomised studies including 
the EUVAS CYCLOPS trial demonstrated that pulsed IV 
CYP at a dose of between 7.5 and 15 mg/kg/pulse has the 
benefit of a lower total cumulative dose but is as effective as 
daily oral therapy in inducing remission.44 However, long-
term relapse rates are likely to be higher, although the risk 
of leucopenia and sepsis is lower. The dose of CYP must 
be adjusted for weight, age, and renal function (Table 2).44 
Mesna (2-mercaptoethanesulfonate sodium), which binds 
the toxic metabolite acrolein, and adequate prehydration, 
particularly before IV therapy, help to reduce the risk of 
bladder toxicity and hemorrhage.
Dosing of glucocorticoids has not so far been subjected to 
randomized trials, and a starting induction dose of 1 mg/kg 
is standard, with subsequent tapering to a maintenance dose 
of ideally not more than 10–15 mg/day at three months or 
when remission is achieved, whichever is later. For rapid 
control of disease, pulsed IV methylprednisolone in doses 
of 0.5–1.0 g daily for three days is often used, but without 
supporting evidence. Side effects, including hypertension, 
obesity, hyperglycemia, cataracts, and osteoporosis, should 
not be underestimated and remain a considerable cause of 
morbidity.
Prophylaxis against infection, peptic ulceration, and 
bone resorption should be standard during induction therapy. 
A combination of agents including Pneumocystis jiroveci 
prophylaxis with trimethoprim-sulphamethoxazole, topical 
oral antifungal treatment, a gastric protective agent, and 
calcium-vitamin D supplementation is usually added to the 
regimen. Biphosphonate therapy is contraindicated with more 
severe degrees of renal impairment but should be used when 
renal function permits.
Plasma exchange
PE is of additional benefit as induction therapy in severe 
renal disease. The EUVAS MEPEX trial compared pulsed IV 
methylprednisolone versus PE, in addition to standard treat-
ment with oral CYP and steroids, in 137 patients with serum 
creatinine 500 µmol/L. It showed that PE decreased the 
risk of progression to end-stage renal disease by 24% at 
12 months.45 Although the mechanism of this is likely to 
relate to rapid removal of ANCA, the depletion of circulating 
cytokines, complement, and coagulation factors may also 
be important. However, PE has not been shown to improve 
overall survival and it is not known whether or not it benefits 
patients with less severe disease. The proposed PEXIVAS 
project aims to study the influence of PE and of a reduced 
dose of steroids on mortality and ESRD in patients with less 
advanced renal impairment (estimated glomerular filtration 
rate of 50 mL/min).
Methotrexate
MTX is a folic acid analog that inactivates the enzyme dihy-
drofolate reductase and thus the production of thymidylate, 
which is essential for DNA replication. MTX has similar 
success rates to CYP in induction of remission in early 
systemic vasculitis without significant renal disease. The 
EUVAS NORAM trial demonstrated that MTX is a less toxic 
alternative to CYP for patients with early systemic disease 
Table 2 Dose modification of pulsed intravenous CYP as used in 
the CYCLOPS trial44
Pulsed CYC dose reductions for renal function and age
Age (years) Creatinine (µmol/L)
  300 300–500
60 15 mg/kg/pulse 12.5 mg/kg/pulse
60–70 12.5 mg/kg/pulse 10 mg/kg/pulse
70 10 mg/kg/pulse 7.5 mg/kg/pulse
See www.vasculitis.org/protocols/CYCLOPS.pdfTherapeutics and Clinical Risk Management 2010:6 258
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and serum creatinine 150 µmol/L,46 achieving equal rates 
of disease remission, albeit at a slower rate. However, MTX 
is contraindicated in significant renal impairment because 
excretion is primarily by the kidney. Side effects include 
mucositis, pneumonitis, myelotoxicity, and hepatotoxicity. 
Dosage may begin at 10 mg/week rising to 25 mg/week or 
0.3 mg/kg if tolerated, and patients should be given folate 
supplementation to minimize adverse reactions. Parenteral 
administration is preferred by some practitioners to minimize 
side effects and for rapidity of response.
Mycophenolate mofetil
MMF inhibits inosine monophosphate deydrogenase, an 
enzyme necessary for purine synthesis, which results in the 
inhibition of T- and B-lymphocyte activity. A recent small 
open-label study in China compared MMF and CYP for 
induction of remission in 35 patients, mainly MPO-positive, 
with serum creatinine 500 µmol/L. This showed higher 
rates of remission and maintenance of normal renal function 
in the MMF group (44%) compared with the CYP group 
(15%) at six months.47 The EUVAS MYCYC trial is compar-
ing MMF and CYP for induction of remission but has yet to 
report the findings. There has been greater interest in the use 
of MMF as a maintenance agent, although recent IMPROVE 
trial results from EUVAS suggest it may be inferior to AZA. 
Gastrointestinal symptoms and opportunistic infections are 
not uncommon.
Maintenance of remission
Maintenance of remission in ANCA-associated vasculitis 
requires long-term immunosuppression in most patients. 
Therapy usually consists of long-term low-dose glucocor-
ticoids together with a second agent. Optimum duration of 
treatment is unclear and this will be addressed by the EUVAS 
REMAIN study which will compare two years and four years 
of prednisolone and AZA maintenance after six months of 
stable remission. At present there is considerable variation in 
practice regarding withdrawal of immunosuppression; how-
ever, most expert practitioners would agree that treatment 
should be continued for a minimum of 18 months, and more 
usually a minimum of 24 months, particularly in PR3-positive 
patients, who have a higher relapse rate.48
Azathioprine
The original NIH regimen continued CYP for 12 months after 
remission. However, 50% of patients still relapsed, often coin-
cident with a decrease in their immunosuppression dose,5,6 
and long-term followup studies have shown the cumulative 
toxicity to be unacceptable. In a 27-year follow-up study of 
145 patients with WG at NIH, there was a 33-fold increase 
in bladder malignancy, a 2.4-fold increase in other malignan-
cies, an 11-fold increase in lymphoma, and infertility rates 
amongst women of 40%–57%.6,49 Therefore, it was necessary 
to develop an alternative less toxic regimen. AZA has been 
widely used for maintenance in Europe, and is metabolized 
into thiopurine nucleotides by the liver, which interferes 
with the enzymes necessary for purine synthesis, leading to 
reduced cellular proliferation. In the EUVAS CYCAZAREM 
trial,3 AZA 2 mg/kg/day was as effective as CYP at main-
taining remission, in combination with steroids, although 
short-term side effects were not reduced. In this randomized 
trial of 155 patients over 18 months, AZA was substituted 
for CYP at 3–6 months and compared with a year of CYP. 
The relapse rate was 17% in both groups and, as a result, 
a switch to AZA following induction of remission by CYP, 
usually achieved within 3–6 months, is now the commonest 
maintenance regimen in use. Side effects include leucopenia 
and hepatotoxicity.
Methotrexate
In the EUVAS NORAM trial, treatment for one year with 
CYP was compared with MTX (see earlier). At 18 months 
there was a 69.5% relapse rate in the MTX group compared 
with 46.5% in the CYP group, although this may be partly 
due to the trial design which stopped all immunosuppression 
at 12 months.46 However, other studies have found significant 
relapse rates with MTX of 37% at 25 months50 and 50% at 
32 months,51 which are not dissimilar to relapse rates with 
AZA or CYP. A direct comparison of AZA and MTX as 
maintenance therapy found no difference in adverse events 
or relapse rates at 12 months.52
Calcineurin inhibitors
Cyclosporin and tacrolimus are both calcineurin inhibitors 
which inhibit T-lymphocyte signal transduction and IL-2 
transcription. Cyclosporin was historically the mainstay of 
immunosuppression for renal transplantation. The newer 
drug tacrolimus has since proven to be more effective in 
preventing rejection53 and has largely superseded cyclo-
sporin. Despite their extensive use in transplantation, and 
in primary glomerulonephritides, the role of these drugs in 
systemic autoimmune diseases has not been systematically 
validated and there are no randomized trials of the use of 
calcineurin inhibitors in AAV. They are sometimes used Therapeutics and Clinical Risk Management 2010:6 259
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as maintenance therapy when more myelotoxic drugs are 
contraindicated. Their potential utility may be inferred from 
the low relapse rates in transplantation, and successful use 
has been reported in case reports and small cohort stud-
ies in AAV.54,55 Cyclosporin has been used as second-line 
maintenance therapy in SLE in uncontrolled trials of small 
numbers with some effect56–58 and tacrolimus has been used 
in induction of remission in renal SLE.59 However, recent 
collaborative trials in AAV have focused on evaluating the 
role of other agents such as MMF and RTX.
Mycophenolate mofetil
MMF is now routinely used long-term to prevent allograft 
rejection in renal transplantation because it has been proven 
to be superior to AZA.60 Consequently, there has been con-
siderable interest in the use of MMF as a maintenance agent 
in place of AZA in vasculitis. One small prospective study of 
14 patients showed that it was well tolerated, although 42% of 
patients relapsed.61 The recently reported EUVAS IMPROVE 
trial compared MMF 2 g/day with AZA 2 mg/kg/day for the 
maintenance of remission in vasculitis, after induction with 
CYP and prednisolone. Perhaps surprisingly, MMF was 
inferior to AZA in the maintenance of remission in AAV 
with time to relapse as the primary endpoint.62 Therefore, it 
seems unlikely that MMF will be used as a standard alterna-
tive to AZA in maintenance, although it could be used as a 
second-line agent in relapsing disease or in those intolerant 
to AZA.
Treatment of relapsing 
or refractory disease
Refractory disease is classified as disease that is unresponsive 
to induction treatment with CYP and steroids or unresponsive 
to standard maintenance treatment. Whilst true refractory 
disease is unusual, up to 50% of patients with AAV will 
relapse over a five-year period.5 Relapse rates are higher 
in patients with WG and in those with PR3-ANCA. Those 
who remain ANCA-positive whilst in remission or become 
ANCA-positive are more likely to relapse.63 However, the 
prognostic significance of a rise in ANCA titer remains 
unclear. A four-fold rise in ANCA titer has been found to be 
predictive of relapse but with a variable time interval (mean 
5.8 months, range 2–12 months) and in the same study 
6/48 patients experienced relapse whilst ANCA titers were 
negative or falling.64 There have been attempts to treat rising 
ANCA titers preemptively with increased immunosuppres-
sion to avoid relapse.65 However, in practice this could lead to 
overtreatment and thus our approach is to observe frequently 
in the face of a rising titer and not to cut immunosuppres-
sion. Relapse has also been associated with nasal carriage 
of Staphylococcus aureus in Wegener’s granulomatosis and 
consequently our practice is to maintain most patients with 
WG on long-term prophylactic cotrimoxazole,30 although 
care needs to be taken with concomitant use of MTX. Most 
patients under close monitoring who have a minor relapse 
on baseline immunosuppression can be managed with a 
temporary increase in oral therapy. Patients with more severe 
relapse will require addition of one or more agents such as 
IV glucocorticoids, CYP, infliximab, or RTX to bring relaps-
ing disease under control. Those with multiple relapses may 
require a change in maintenance regimen.
Leflunomide
Leflunomide is an oral alternative to AZA or MTX for 
maintenance in relapsing disease. The mechanism of action 
of leflunomide is not fully understood but may be related to 
its ability to inhibit de novo pyrimidine biosynthesis through 
the inhibition of the enzyme dihydroorotate dehydrogenase. 
Leflunomide has been shown to be more effective at main-
taining remission compared with methotrexate but with an 
excess of adverse events.66 Lower dosing regimens have yet 
to be evaluated.
Biological therapies
TNF blockade
Infliximab is a chimeric monoclonal antibody which binds 
soluble and transmembrane forms of TNF-α. Blockade of 
TNF-α with infliximab has been found to be effective for 
inducing and maintaining remission when used with con-
ventional therapy in an uncontrolled but reasonably large 
study, and has a steroid-sparing effect, although there is an 
increased rate of severe infections.67 However, a retrospec-
tive surveillance study in patients with rheumatoid arthritis 
treated with TNF inhibitors (predominantly infliximab) 
also demonstrated an excess risk of active tuberculosis 
infection.68 In contrast with infliximab, the soluble TNF-
receptor blocker etanercept was not effective at maintaining 
remission. Etanercept is a fusion protein consisting of two 
extracellular p75 TNF-α-receptor domains linked to the Fc 
portion of human IgG1. A randomized controlled trial of etan-
ercept in 180 patients with WG, mainly without severe renal 
disease, showed no benefit in the induction or maintenance 
of remission (although prednisolone was withdrawn at six 
months) and demonstrated a high rate of treatment-associated Therapeutics and Clinical Risk Management 2010:6 260
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  complications and an excess of solid organ tumors.69 It is not 
clear why these two mechanisms of TNF-α blockade gave 
rise to such different outcomes, and this may relate to their 
  differing biologic effects. The Wegener's Granulomatosis 
Etanercept Trial also enrolled a significantly greater propor-
tion of relapsing patients into the etanercept arm compared 
with more treatment-naïve patients in the control arm. 
Whether this biased the outcomes is unclear.
B-cell depletion
The success of B-cell depletion with the anti-CD20 chimeric 
monoclonal antibody RTX in refractory disease70 has led to 
its ongoing evaluation as a remission induction agent. First 
licensed for B-cell lymphoma, it has been used extensively 
in hematologic patients and now increasingly in autoimmune 
disease, including rheumatoid arthritis. RTX is generally well 
tolerated, but side effects include leucopenia and infection. 
Rare reports of progressive multifocal leucoencephalopathy 
in association with RTX and other biologic agents are under 
evaluation.71 The EUVAS RITUXVAS trial compared RTX 
and two doses of CYP with a standard CYP regimen in 
44 patients and found similar remission rates and adverse 
events, and will be published shortly.72 Follow-up remains 
limited and more prolonged evaluation may be required to 
evaluate the rates of relapse following B-cell reconstitution. 
The ongoing RAVE trial compares RTX and steroids with 
a standard CYP induction regimen in 200 patients, and initial 
reports suggest equivalent effectiveness at six months.73 The 
RATTRAP trial will compare RTX and infliximab in AAV . 
Duration of response to RTX can be variable but is frequently 
prolonged with a median time of 12–16 months.74
Other therapies for  
refractory disease
A number of other therapies have been used in small numbers 
of patients but experience with these is currently limited. 
15-Deoxyspergualin is a synthetic version of a protein iso-
lated from Bacillus laterosporus, which binds to chaperone 
proteins important in the activation of nuclear factor κB and 
prevents its activation. It has been trialed in patients with 
refractory disease and demonstrated an improvement in 
disease parameters and complete remission in 45% but led to 
recurrent leucopenia.75 Alemtuzamab is a humanized mono-
clonal antibody that specifically binds CD52 on the surface of 
monocytes and lymphocytes. It is used in B-cell lymphoma, 
allogeneic stem cell transplantation, and renal transplantation. 
Its use has been reported in a small number of patients with 
WG with some effect,76 but relapse rates and adverse events 
are common.77 Antithymocyte globulin (ATG) is a collection 
of polyclonal antibodies directed against the surface antigens 
of activated T-cells and has been used in refractory patients 
with WG in the EUVAS SOLUTION trial.34 T-cell depletion 
with ATG produced a 75% remission rate but the development 
of an antiglobulin response limits repeated therapy. Both ATG 
and alemtuzumab cause profound immunosuppression and 
a high rate of severe infections in high-risk subgroups, such 
as those with renal failure. Of note, both these agents were 
used in cohorts of patients already exposed to significant 
immunosuppression, and their role in disease remission 
in patients naïve to therapy may need to be revisited. IV 
immunoglobulin has been used to induce remission with 
significant success78,79 either as sole therapy or for its treat-
ment-sparing effect. Although the cost is prohibitive, it may 
be a useful and safe adjunct in sepsis or pregnancy where 
standard immunosuppression is contraindicated.
Future prospects in therapy
The success of RTX has led to the development of further 
agents for B-cell depletion. A humanized monoclonal anti-
CD20 antibody, ocrelizumab, has been trialed in a number 
of autoimmune disorders including rheumatoid arthritis,80 
and ofatumumab is a fully human anti-CD20 undergoing 
Phase III trials, which has been used in lymphoproliferative 
and autoimmune disorders.81
Another approach to modulation of B-cells has been 
proposed following the finding that B-lymphocyte stimula-
tor (BLyS)/B-cell activating factor is a potential mediator 
in autoimmune disease.82 Belimumab, a human anti-BLyS 
monoclonal antibody, has already shown promise in Phase III 
trials in SLE.83 BLyS is a member of the TNF superfamily 
of cytokines and is expressed by cells of myeloid origin with 
a role in B-cell differentiation, proliferation, and immuno-
globulin production. Neutrophils are another important 
source of BLyS.84 Serum levels of BLyS have been found 
to be elevated in SLE85 and AAV .86 A proliferation-inducing 
ligand (APRIL) is another member of the TNF family87 and 
a potent stimulator of B-cell maturation and differentiation. 
Atacicept is a recombinant fusion protein which blocks 
both BLyS and APRIL by blocking their receptor TACI 
  (transmembrane activator and calcium modulator and 
cyclophilin ligand interactor) and has been used in SLE and 
rheumatoid arthritis.88 The role of these B-cell modulating 
agents in AAV remains to be explored.
A number of other biologic agents which manipulate 
other aspects of the immune response are either being trialed 
or are in early use in other diseases. Abatacept, a fusion Therapeutics and Clinical Risk Management 2010:6 261
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protein of CTLA4-Ig which selectively modulates T-cell 
co-stimulation by blocking the engagement of CD28, would 
theoretically be of benefit in AAV, although the EUVAS 
ABAVAS trial was terminated early due to slow recruitment. 
The alternative pathway of complement has been shown to 
have a role in a murine model of MPO-ANCA vasculitis.22 
Addition of a C5-inhibiting monoclonal antibody in this 
model markedly protected against glomerulonephritis.89 
Eculizumab is a monoclonal antibody to C5a used in the 
treatment of paroxysmal nocturnal hemoglobinuria. If a role 
for complement can also be demonstrated in the pathology 
of human AAV then modulation of this pathway may be a 
therapeutic prospect. An anti-IL-5 monoclonal antibody, 
mepolizumab, has been effective in hypereosinophilic 
syndromes90 and may be of use in CSS which is associated 
with elevated IL-5 and eosinophilia. Tocilizumab, an anti-
IL-6 monoclonal, has been used in refractory rheumatoid 
arthritis91 and may be more widely applicable in autoim-
mune diseases.
The Th17 subset of T-helper cells which produce 
IL-17 has been implicated in the pathogenesis of a num-
ber of experimental and human autoimmune conditions. 
This is particularly of relevance to AAV because IL-17 
deficient mice are protected from nephrotoxic nephritis92 
and from MPO-ANCA vasculitis,93 and Th17 cells have 
recently been shown to induce proliferative glomeru-
lonephritis in mice.94 Clinical trials of IL-17 blockade 
are already underway in autoimmune uveitis, psoriatic 
arthritis, ankylosing spondylitis, and Crohn’s disease 
(www.clinicaltrials.gov) and may have potential for use in 
AAV. Inhibition of spleen tyrosine kinase (Syk) has been 
trialed in rheumatoid arthritis95 and has been shown in 
our laboratory to prevent and treat nephrotoxic nephritis 
in rats.96 Syk inhibition might be an important therapeutic 
target in AAV. Lastly, stem cell transplantation aims to 
restore immunologic tolerance by eliminating autoreactive 
clones followed by T-cell reconstitution. There have been 
some cases of hematopoietic stem cell transplantation 
in patients with unresponsive ANCA-positive vasculitis 
but ANCA-associated disease relapse is not completely 
prevented, and therefore its value has yet to be confirmed 
prospectively.97
Conclusion
Current approaches to treatment in induction and mainte-
nance of AAV are well established (Table 3).98 The European 
League against Rheumatism (EULAR) guidelines for the 
management of small and medium vessel vasculitis have 
recently been published99 and the role of newer agents such 
as MMF is being defined by clinical trials. The success and 
safety profile of rituximab in refractory disease has led to 
trials in maintenance and induction therapy which may see it 
recommended as standard practice, although high cost may 
limit its use. The wide range of newer biologic agents now 
available brings huge possibilities for immunotherapy in 
relapsing or refractory disease. However, the rarity of AAV 
is a hindrance to developing an evidence base for practice. 
Therefore, international cooperation and collaborative 
  trials remain essential if patients are to receive appropriate, 
  effective therapy.
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Table 3 Suggested schema for the management of ANCA-associated vasculitis, adapted and updated from Pallan et al98
Disease severity EUVAS definition Induction therapy Maintenance therapy
Localized Upper and/or lower respiratory 
tract disease without any other 
  systemic involvement or constitutional 
  symptoms
Methotrexate and steroids Low-dose steroids plus azathioprine 
or leflunomide or methotrexate  
(+ trimethoprim-sulphamethoxazole 
also added in WG)
Early systemic Any, without organ-threatening  
or life-threatening disease
Methotrexate or cyclophosphamide 
and steroids
Low-dose steroids plus azathioprine 
or methotrexate
Generalized Renal or other organ threatening 
disease, serum creatinine 500 µmol/L 
(5.6 mg/dL)
Cyclophosphamide (or rituximab) 
and steroids
Low-dose steroids plus azathioprine  
Mycophenolate mofetil as second-line 
agent
Severe Renal or other vital organ failure, serum 
creatinine 500 µmol/L (5.6 mg/dL)
Cyclophosphamide and steroids plus 
plasma exchange (rituximab instead 
of CYC)
Low-dose steroids plus azathioprine  
Mycophenolate mofetil as second-line 
agent
Refractory  Progressive disease unresponsive to 
glucocorticoids and cyclophosphamide
Deoxyspergualin, antithymocyte 
globulin, or rituximab
No consensus Therapeutics and Clinical Risk Management 2010:6 262
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